A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.

Trial Profile

A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2011

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms FULLSCALE
  • Most Recent Events

    • 26 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top